Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x100px
Document › Details

Sygnis AG. (5/8/17). "Press Release: Sygnis AG Plans to Acquire Profitable Innova Biosciences Ltd. for EUR 8 Million in Cash and up to 3.5 Million Shares [Not for USA, Canada, Japan and Australia]". Madrid & Heidelberg.

Organisations Organisation Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
  Group 2invest (Group)
  Organisation 2 Innova Biosciences Ltd.
  Group 2invest (Group)
Products Product reagents (bio/biochemical)
  Product 2 Lightning-Link™ antibody labeling system
Index terms Index term Innova Biosciences–Genetrix (ES): investment, 201705–201707 acquisition €8m cash + 2m Sygnis shares plus up to 1.5m shares by Sygnis AG
  Index term 2 Genetrix (ES)–SEVERAL: investment, 201705– capital increase up to €10m w rights offering + private placement Sygnis AG
Persons Person Lanckriet, Heikki (Expedeon 201111 CEO + Founder)
  Person 2 Gee, Nick (Innova Biosciences Ltd 201111 CEO + CSO)

Record changed: 2023-06-05


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for 2invest (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px

» top